Table 1.
Lesion type | Size range (μm) | Appearance on AOSLO imaging | Increased reflectivity | Longitudinal follow-up | Shadowing of cones | Detectable in SDOCT (%) | Blood flow visible on AOSLO imaging | |
---|---|---|---|---|---|---|---|---|
Confocal | Multiply scattered light | |||||||
Microaneurysms (n = 52) | 46–168 | Round/oval lesions with dark, thickened vessel walls | Better defined vessel walls than in confocal imaging | 46% intraluminal 35% vessel wall | No | Yes | 58 | Feeder vessels and intraluminal blood flow |
IRMA (n = 20) | 69–360 | Distinct convoluted vessel formation | Better defined vessel walls than in confocal imaging | No | No | Yes | 90 | Feeder vessels and intraluminal blood flow |
NV (n = 7) | 283–1406 | Distinct convoluted vessel formation | Sharply defined vessel walls, distinction to fibrotic tissue, perfused and nonperfused vessels | No | Yes, under treatment of 0.3 ranibizumab | Yes | 100 | Feeder vessels and intraluminal blood flow, nonperfused vascular channels |
Hemorrhages (n = 5) | 52–234 | Dark homogenous patches | Dark homogenous patches, same information as in confocal imaging | No | No | Yes | No | n/a |
CWS (n = 4) | 432–954 | RNFL striation pattern disrupted, hyperreflective, fluffy | Less RNFL reflectivity | Yes | No | No | 100 | n/a |
HE (n = 11) | 27–745 | Highly reflective distinct granular patches | Highly reflective distinct granular patches, same information as in confocal imaging | Yes | Yes, under treatment of 0.3 ranibizumab | Yes | 91 | n/a |
Cysts (n = 14) | 72–1086 | Blurred dark shadows | Clear delineation of cyst boundaries and wall structures | No | No | Inconsistent | 100 | n/a |
AOSLO: adaptive optics scanning laser ophthalmoscopy; SDOCT: spectral domain optical coherence tomography; IRMA: intraretinal microvascular abnormalities; NV: neovascularization; CWS: cotton wool spot; RNFL: retinal nerve fiber layer; HE: hard exudates.